About this trial
Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health. Offering novel designs with significantly lower E\&B leads to a reduction in UTIs and improves QoL. Reducing hospital admissions (from 3 to 1 per patient, annually) would free \>100,000 bed-nights, allowing the elderly to regain independence. Our proposed research could have a significant impact towards fulfilling the 'healthy-ageing' Grand Challenge. Additionally, the novel stent reduces prevalence of infections and therefore, of antibiotic prescriptions contributing to the Global AMR challenge.
Eligibility criteria
Qualifiers
Aged 18 years or over
Ureteric stents clinically indicated either due to kidney stones or abdominal/pelvic cancers compressing ureters
Previous experience with ureteric stents
Awaiting insersion/replacement of stents
Disqualifiers
Expected survival <4months
Unfit for stent insertion
Unable to comply with study processes Pregnancy
Trial design
Treatments tested in this trial
- Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B)
- Qualitative interview
Treatment groups
Sponsors and collaborators
University of Southampton
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Collaborator
National Institute for Health Research, United Kingdom
Collaborator
University College London Hospitals
Collaborator